- Home
- PBYI vs HUMA Comparison
PBYI vs HUMA Comparison
Compare PBYI & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | HUMA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 236.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | HUMA |
|---|---|---|
| Price | $5.96 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $10.13 |
| AVG Volume (30 Days) | 372.8K | ★ 4.2M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $698.97 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $1.04 |
| 52 Week High | $6.12 | $5.66 |
Technical Indicators
Market Signals| Indicator | PBYI | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 66.14 | 37.60 |
| Support Level | $5.51 | $1.04 |
| Resistance Level | $5.73 | $1.17 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 95.76 | 16.67 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.